Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / AGN:CC - Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

AGN:CC - Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

Algernon Pharmaceuticals Inc.

(NewsDirect)

Algernon Pharmaceuticals CEO Christopher Moreau said the companyhas announced that its subsidiary Algernon NeuroScience has dosed thefirst subject in the Phase 1 DMT clinical stroke study. Moreau toldProactive this dosing was in the Netherlands where the study is beingconducted at the Centre for Human Drug Research in Leiden. The firstpart of the study will use a single-escalating dose design aimed atidentifying a safe and tolerable dose that will not producepsychedelic effects.

ProactiveCanada Financial News

ContactDetails

Proactive Canada

ProactiveCanada

+1 604-688-8158

na-editorial@proactiveinvestors.com

Copyright (c) 2023 TheNewswire - All rights reserved.

Stock Information
Company Name: Algernon Pharmaceuticals Inc.
Stock Symbol: AGN:CC
Market: CNQC
Menu
AGN:CC AGN:CC Quote AGN:CC Short AGN:CC News AGN:CC Articles AGN:CC Message Board
Get AGN:CC Alerts

News, Short Squeeze, Breakout and More Instantly...